Novel theranostic nanoplatform for complete mice tumor elimination via MR imaging-guided acid-enhanced photothermo-/chemo-therapy

Li, Bei; Tang, Jie; Chen, Wei-Yu; Hao, Guanyu; Kurniawan, Nyoman D.; Gu, Zi; Xu, Zhi Ping

doi:10.1016/j.biomaterials.2018.05.055

Cited by 100 publications

(108 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, compared to spherical nanoparticles, the plate‐like morphology of LDH is generally subjected to torques leading to tumbling and rotation and consequently increased lateral drift of nanoparticles toward blood vessel walls . In a recent study reported by our team, 3.6% of intravenously injected Cu‐LDH accumulated in the tumor, which exhibited significantly higher tumor accumulation than other nanoparticles (0.7% on average) …”

Section: Enhanced Accumulation By Targeting Strategymentioning

confidence: 88%

Section: Selectivity By Endogenous Stimuli‐responsementioning

confidence: 99%

“…First, LDHs are able to dissolve/disintegrate in the physiological environment, especially in acidic compartments (e.g., the tumor microenvironment and acidic vesicles such as endosomes) ( Figure a), which helps minimize safety risks caused by long‐term in vivo accumulation . For example, we recently noted that BSA‐coated Cu‐LDH nanoparticles (25 nm) accumulated in the tumor tissue on the first day after administration, while the accumulated LDH nanoparticles disappeared in the following 2 days due to biodegradation in the slightly acidic tumor microenvironment . Second, the biodegraded products of LDH, including cations (e.g., Mg 2+ ), anions (e.g., Cl − , NO 3 − , CO 3 2− ), hydroxide (e.g., Al(OH) 3 ), and H 2 O, are biofriendly to the host organism.…”

Section: Biosafety Evaluationmentioning

confidence: 99%

“…Interestingly, when LDH was administered intraperitoneally, its distinct morphological and histopathological changes were observed in a few lungs of Balb/c mice, especially for the LDH nanoparticles with small size (e.g., 50 and 100 nm) . In recent years, with the fast advances in developing LDH nanomedicine, the biosafety evaluation of LDHs has attracted significantly increased attention, especially focusing on LDHs with different metal composition (e.g., Cu or Fe containing LDH), interlayer anions (e.g., NO 3 ‐LDH, CO 3 ‐LDH, PO 4 ‐LDH), surface coatings (e.g., BSA, PEG, formamide), and aggregation status . Biosafety evaluation of Fe, Cu, or Mn‐containing LDHs showed minimal toxicity at their therapeutic doses via intravenous administration.…”

Section: Biosafety Evaluationmentioning

confidence: 99%

“…caused by in vivo long time accumulation of nanoparticles . Second, protonation of OH groups of the LDH microstructure in the acidic environment enables the formation of structural vacancy and new coordinated H 2 O molecules for high‐performance phototherapy and ultrasensitive magnetic resonance imaging . Especially, the brucite‐like layer of LDH can be facilely incorporated with various metal cations via isomorphic substitution to construct functional nanomaterials as long as the metal cations M 2+ have the similar radii to that of Mg 2+ .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

2D Layered Double Hydroxide Nanoparticles: Recent Progress toward Preclinical/Clinical Nanomedicine

et al. 2019

Self Cite

View full text Add to dashboard Cite

2D nanomaterials represent one of the next‐generation biomaterials with versatile physicochemical advantages that allow for diverse biomedical applications in disease diagnosis, prevention, and treatment. In particular, layered double hydroxide (LDH) nanoparticles, as a typical 2D nanomaterial, have recently shown unprecedented advances in controllable and simplified chemical construction, versatile surface engineering, and comprehensive biological investigation. To realize in vivo biomedical applications, recent efforts have been substantially devoted to a few critical aspects of LDH nanomedicine including nanoparticle stability in physiological environments, accumulation at the disease‐targeted site, selective biological response to the nanoparticle, systematic biosafety examination, integration with multiple diagnostic and therapeutic modalities, and the adjuvant activity and suitability for gene‐based and protein‐based vaccines, which are herein comprehensively reviewed. The challenges and future development strategies of LDH nanomedicine are also discussed toward practical biomedical applications to benefit patients.

show abstract

Section: Enhanced Accumulation By Targeting Strategymentioning

confidence: 88%

Section: Selectivity By Endogenous Stimuli‐responsementioning

confidence: 99%

Section: Biosafety Evaluationmentioning

confidence: 99%

Section: Biosafety Evaluationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

2D Layered Double Hydroxide Nanoparticles: Recent Progress toward Preclinical/Clinical Nanomedicine

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

Engineering a Therapy‐Induced “Immunogenic Cancer Cell Death” Amplifier to Boost Systemic Tumor Elimination

Hao

Sun

et al. 2020

Adv Funct Materials

Self Cite

108

View full text Add to dashboard Cite

Immunogenic cancer cell death (ICD) is drawing worldwide attention as it allows dying cancer cells to regulate the host's anti-tumor immune system and awaken immunosurveillance. Thus, effectively activating therapy-induced ICD is of great clinical significance to raise systemic anti-tumor immunity and eradicate post-treatment/abscopal cancer tissues. Enhanced cytotoxic reactive oxygen species (ROS) generation in cancer therapy has been positively correlated to ICD induction, which inspires design of a therapy-induced ICD amplifier. The nanohybrid amplifier (FeOOH@STA/Cu-LDH) is devised based on Cu-containing layered double hydroxide (Cu-LDH), incorporating ROS inducer (FeOOH nanodots), ROS generation booster (Cu-LDH for photothermal therapy), and heat shock protein inhibitor (STA). Treating 4T1 tumor cells with this amplifier translocates calreticulins (CRT, one of main ICD signals) on the surface of dying cancer cells, which achieves the maximum at fever-type temperature (40-42 °C). To demonstrate immunotherapeutic efficacy of this nanohybrid, 4T1 tumor-bearing mouse model is established with primary and abscopal tumors. Significantly, only one treatment with the ICD amplifier eradicates the primary tumor and inhibits the abscopal tumor growth upon fever-type heating and induces more cytotoxic T lymphocytes in abscopal tumors and spleens after treatment for 1 week. This research thus provides a new insight into nanomaterial-mediated tumor immunotherapy.

show abstract

Trifunctional Graphene Quantum Dot@LDH Integrated Nanoprobes for Visualization Therapy of Gastric Cancer

Sun

et al. 2021

Adv Healthcare Materials

View full text Add to dashboard Cite

Visualization technology has become a trend in tumor therapy in recent years. The superior optical properties of graphene quantum dots (GQDs) make them suitable candidates for tumor diagnosis, but their tumor targeting and drug‐carrying capacities are still not ideal for treatment. Sulfur‐doped graphene quantum dots (SGQDs) with stable fluorescence are prepared in a previous study. A reliable strategy by associating layered double hydroxides (LDHs) and etoposide (VP16) is designed for precise visualization therapy. Trifunctional LDH@SGQD‐VP16 integrated nanoprobes can simultaneously achieve targeted aggregation, fluorescence visualization, and chemotherapy. LDH@SGQD‐VP16 can accumulate in the tumor microenvironment, owing to pH‐sensitive properties and long‐term photostability in vivo, which can provide a basis for cancer targeting, real‐time imaging, and effect tracking. The enhanced therapeutic and attenuated side effects of VP16 are demonstrated, and the apoptosis caused by LDH@SGQD‐VP16 is ≈2.7 times higher than that of VP16 alone, in HGC‐27 cells. This work provides a theoretical and experimental basis for LDH@SGQD‐VP16 as a potential multifunctional agent for visualization therapy of gastric cancer.

show abstract

Novel theranostic nanoplatform for complete mice tumor elimination via MR imaging-guided acid-enhanced photothermo-/chemo-therapy

Cited by 100 publications

References 62 publications

2D Layered Double Hydroxide Nanoparticles: Recent Progress toward Preclinical/Clinical Nanomedicine

2D Layered Double Hydroxide Nanoparticles: Recent Progress toward Preclinical/Clinical Nanomedicine

Engineering a Therapy‐Induced “Immunogenic Cancer Cell Death” Amplifier to Boost Systemic Tumor Elimination

Trifunctional Graphene Quantum Dot@LDH Integrated Nanoprobes for Visualization Therapy of Gastric Cancer

Contact Info

Product

Resources

About